Pseudobulbar affect (PBA) is a condition that's characterized by episodes of sudden uncontrollable and inappropriate laughing or crying. Pseudobulbar affect typically occurs in people with certain neurological conditions or injuries, which might affect the way the brain controls emotion.
PBA is affecting large number of people across the globe. Pseudobulbar affect (PBA) is a condition that's characterized by episodes of sudden uncontrollable and inappropriate laughing or crying. It is witnessed among patient suffering from multiple sclerosis (MS), traumatic brain injury, and Alzheimer's disease. According to CDC, in 2020, as many as 5.8 million Americans were living with Alzheimer’s disease. In 2017, around 2 million people in the U.S. were suffering from pseudobulbar affect. Pseudobulbar affect is primarily associated with neurological disorders, and around 30% to 35% patients suffer from depression. Prevalence of pseudobulbar affect is higher in people with neurological disorders, which is around 5% to 50%. Rapid increase in number of patient suffering from PBA and increasing awareness among consumers related to availability of advanced treatments are factors expected to drive the growth of global pseudobulbar treatment market.
Increasing R&D activities by major players, rise in clinical trial activities for development of new drugs, and approvals from the regulatory bodies are factors expected to segment the growth of pseudobulbar treatment market. Players are focused on enhancing the business through introduction of new solutions this is expected to attract new customers.
In 2018, Avanir pharmaceuticals, a global drug manufacturer launched a national, multi-channel campaign aimed at raising awareness of Pseudobulbar Affect, an often ignored and under treated neurologic condition that occurs secondary to certain neurologic injury or disease.
In 2020, Janssen Pharmaceutical Companies, a global drug manufacturer received approval from the U.S. Food and Drug Administration (FDA) for “SPRAVATO”. SPRAVATO is the first and only approved medicine that has been shown to reduce depressive symptoms within 24 hours, providing a new option for significant symptom relief until a longer-term, comprehensive treatment plan can take effect.
Favorable business policies by the government and emergence of small & Mid-size enterprises with innovative solutions are factors expected to boost the target market growth. Factors such as high cost associated to R&D activities of drugs and strict government regulations related to product approval are expected to hamper the growth of global pseudobulbar treatment market. In addition, lack of developed infrastructure in developing countries for R&D activities is expected to challenge the growth of target market. However, huge investment by manufacturers for drug discovery and inclination towards tracking the untapped market in developing regions are factors expected to create new opportunities for players operating in the pseudobulbar treatment market over the forecast period. In addition, government of developing countries focus on strengthening the regional manufacturing capabilities is expected to attract players further responsible for the revenue growth of the market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global pseudobulbar treatment market due to high patient pool suffering from neurological disorders. High investment by the government and collaborative approach between public-private players for product development are factors expected to support the growth of pseudobulbar treatment market. In addition, presence of large number of players operating in the country and increasing partnership activities for business expansion are factors expected to support the regional market growth.
The global pseudobulbar treatment market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Pseudobulbar Treatment Market Segment Analysis, 2019
The global pseudobulbar treatment market is segmented into treatment, drugs, route of administration, and end use. The treatment segment is divided into medication, supportive care, others. The drugs segment is bifurcated into pseudobulbar treatments, tricyclic antidepressants, nuedexta, others. Among drugs the tricyclic antidepressants segment is expected to witness faster growth in the target market. The players profiled in the report are Avanir Pharmaceuticals, Inc., Novartis AG, Mylan N.V., Lupin, Teva Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories Ltd.
Market By Treatment
Market By Drugs
Market By Route of Administration
Market By End-Users
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Rapid increase in number of patient suffering from PBA and increasing awareness among consumers related to availability of advanced treatments are factors expected to drive the growth of global pseudobulbar treatment market.
In route of administration the oral segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Avanir Pharmaceuticals, Inc., Novartis AG, Mylan N.V., and Lupin
The North America is expected to account for major revenue share in the global market.
Factors such as high cost associated to R&D activities of drugs and strict government regulations related to product approval are expected to hamper the growth of global pseudobulbar treatment market.